HKSE - Delayed Quote • HKD
Hansoh Pharmaceutical Group Company Limited (3692.HK)
At close: 4:08 PM GMT+8
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | 15 |
| Avg. Estimate | 0 | 0 | 0 | 0.51 |
| Low Estimate | 0 | 0 | 0 | 0.45 |
| High Estimate | 0 | 0 | 0 | 0.56 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 12 | 14 |
| Avg. Estimate | -- | -- | 10.39B | 11.13B |
| Low Estimate | -- | -- | 11.13B | 10.68B |
| High Estimate | -- | -- | 11.82B | 12.33B |
| Year Ago Sales | -- | -- | 11.64B | 10.39B |
| Sales Growth (year/est) | -- | -- | -10.70% | 7.10% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0.51 |
| 7 Days Ago | 0.27 | 0 | 0.53 | 0.52 |
| 30 Days Ago | 0.27 | 0 | 0.53 | 0.52 |
| 60 Days Ago | 0.27 | 0 | 0.53 | 0.51 |
| 90 Days Ago | 0.27 | 0 | 0.53 | 0.52 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | 3692.HK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.80% |
| Next Qtr. | -- | -- | -- | 9.60% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | 13.36% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker
Related Tickers
2186.HK Luye Pharma Group Ltd.
2.610
-0.38%
2877.HK China Shineway Pharmaceutical Group Limited
9.450
+2.38%
IPN.PA Ipsen S.A.
105.80
-0.47%
0013.HK HUTCHMED (China) Limited
26.000
-0.38%
SUPN Supernus Pharmaceuticals, Inc.
28.87
-0.45%
MRK.DE Merck KGaA
144.75
-1.36%
PCRX Pacira BioSciences, Inc.
26.10
-2.50%
COLL Collegium Pharmaceutical, Inc.
34.77
-1.92%
ALKS Alkermes plc
23.76
-1.04%
AMPH Amphastar Pharmaceuticals, Inc.
38.65
-3.50%